Target intelligence / Profile preview

Autoantibody-producing B cell

Molecular classification
Lymphocyte, B cell (B lymphocyte), Plasma cell (if terminally differentiated), Antibody-secreting cell, Professional antigen-presenting cell (APC)
01

Overview

"Autoantibody-producing B cell" refers to a B lymphocyte that has differentiated to secrete antibodies targeting the body's own tissues or antigens (autoantibodies), a hallmark of autoimmune disease pathogenesis. This functional state can occur in various stages of B cell differentiation, including short-lived plasmablasts and long-lived plasma cells. These cells play a pivotal role in the development and perpetuation of autoimmunity by breaking tolerance to self and facilitating chronic inflammation. Therapeutic strategies in diseases such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis often aim to selectively deplete or functionally inhibit these pathogenic B cells, but face challenges tied to their similarity to normal, protective antibody-producing cells and their sometimes limited surface marker expression when fully differentiated.

Other names
autoreactive B cellautoantigen-specific B cellpathogenic B cellplasma cell (when terminally differentiated and antibody-secreting)antibody-secreting cell (when transiently differentiated)
02

Mechanism of action

B cell depletion (targeting surface markers such as CD20); Inhibition of B cell survival factors (e.g., BAFF/BLyS inhibition); Blocking B cell maturation or differentiation pathways

03

Biological functions

Antibody production (specifically autoantibodies)Immune response regulationAntigen presentationCytokine secretionContribution to humoral immunity
04

Disease associations

AutoimmunityInflammatory diseaseOther (pathogenic in specific organ/tissue autoimmune syndromes, e.g., CNS autoimmunity)
05

Safety considerations

Immunosuppression (risk of infection due to general B cell depletion)Loss of protective antibody responsesHypogammaglobulinemia
06

Interacting drugs

Rituximab (anti-CD20 antibody, depletes B cells)

3 more in the full profile.

07

Biomarkers

Serum autoantibody levels (e.g., anti-dsDNA, anti-MuSK, anti-CCP)Circulating plasmablasts (CD27^hi^ CD38^hi^ cells)B cell surface markers (CD19, CD20, CD27, CD38)

Beyond the preview

Go deeper on Autoantibody-producing B cell.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Autoantibody-producing B cell.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call